The announcement, which also included a significant SCi share purchase by Warner Bros, as well as a new share placement at 35 pence per share, failed to stimulate the company's stock, which has fallen from 520 pence last July to …
MADISON, Wis. - Members of the city's Judge Doyle Square negotiating committee say they are waiting for developer Bob Dunn to answer if the 46 percent stock drop of biotech company Exact Sciences could impact the project. The city …
CEL-SCI Corporation (NYSE: CVM), a late-stage oncology company, today announced that it intends to offer and sell common stock and warrants, subject to market and other conditions, in an underwritten public offering. The shares and …
* Cel-Sci Corp - a 1-for-25 reverse split was authorized for its outstanding shares of common stock Source text for Eikon: Further company coverage: Our Standards:The Thomson Reuters Trust Principles.
June 28 (Reuters) - Applied DNA Sciences Inc: * Applied DNA Sciences says entered into subscription agreements
What's the outlook for Gilead Sciences' stock? Over the short run, that question is next to impossible to answer. Over the long run, though, investors can project how well Gilead stock (or any other stock, for that matter) should perform with at …
Exact Sciences (NASDAQ: EXAS) announced that Jefferies LLC and Robert W. Baird & Co. Incorporated, the underwriters of the Company’s previously announced public offering of 7,000,000 shares of common stock, are reoffering the shares …
In May, Andrew Left of Citron Research blasted Exact Sciences (NASDAQ: EXAS), calling the stock "a poster child for what goes wrong when Wall Street gets a hold of a healthcare concept with no discrimination for whether it's good or …
This Tuesday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Gilead …